| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/22/2009 | EP2049465A2 Processes for preparing solid states of o-desmethylvenlafaxine succinate |
| 04/22/2009 | EP2049201A2 Phosphate diester amides |
| 04/22/2009 | EP2049200A2 Novel inhibitors of beta-lactamase |
| 04/22/2009 | EP2049199A1 Compositions for the treatment of chronic degenerative inflammatory conditions |
| 04/22/2009 | EP2049155A2 Antitumor combinations containing taxane derivatives |
| 04/22/2009 | EP2049143A1 Improved antibacterial antisense oligonucleotide and method |
| 04/22/2009 | EP2049139A2 Treatment of ras-expressing tumors |
| 04/22/2009 | EP2049137A2 Salicylanilides enhance oral delivery of therapeutic peptides |
| 04/22/2009 | EP2049136A1 Mitochondria-targeted antioxidants |
| 04/22/2009 | EP2049134A2 Compositions comprising rosehip and other active agents for the treatment of inflammatory disorders |
| 04/22/2009 | EP2049129A1 Catecholamine receptor modulation |
| 04/22/2009 | EP2049127A2 N-methanocarba derivatives to treat cardiac diseases |
| 04/22/2009 | EP2049126A2 Liposome treatment of viral infections |
| 04/22/2009 | EP2049125A2 Treatment of cancer with 2-deoxygalactose |
| 04/22/2009 | EP2049124A2 Phosphorus derivatives as histone deacetylase inhibitors |
| 04/22/2009 | EP2049123A1 Delayed-release glucocorticoid treatment of rheumatoid disease |
| 04/22/2009 | EP2049122A1 Methods and compositions for inhibiting angiogenesis |
| 04/22/2009 | EP2049121A1 Methods and compositions for promoting activity of anti-cancer therapies |
| 04/22/2009 | EP2049120A1 Urotensin ii receptor antagonists |
| 04/22/2009 | EP2049119A2 Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea |
| 04/22/2009 | EP2049118A1 Morpholinyl and pyrrolidinyl analogs |
| 04/22/2009 | EP2049117A2 Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects |
| 04/22/2009 | EP2049116A2 Hepatitis c virus inhibitors |
| 04/22/2009 | EP2049115A2 Alkyne-substituted pyridone compounds and methods of use |
| 04/22/2009 | EP2049114A2 Hepatitis c virus inhibitors |
| 04/22/2009 | EP2049113A2 Medicament for the enhancement of cognitive function and neuroprotection |
| 04/22/2009 | EP2049112A2 Treating infections and sequelae thereof with combined dissociated glucocorticoid receptor agonists and anti-infective agents |
| 04/22/2009 | EP2049111A2 Fungicidal azocyclic amides |
| 04/22/2009 | EP2049110A2 Bridged diazepan orexin receptor antagonists |
| 04/22/2009 | EP2049109A2 Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia |
| 04/22/2009 | EP2049108A1 Treatment of endocrine dysfunction using iron chelators |
| 04/22/2009 | EP2049107A2 Substituted imidazolone derivatives, preparation and uses |
| 04/22/2009 | EP2049105A2 Anti-microbial photodynamic therapy |
| 04/22/2009 | EP2049104A2 Pyrrolidinone anilines as progesterone receptor modulators |
| 04/22/2009 | EP2049103A2 Inhibitors of undecaprenyl pyrophosphate synthase |
| 04/22/2009 | EP2049102A2 Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof |
| 04/22/2009 | EP2049101A2 Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof |
| 04/22/2009 | EP2049100A2 Therapeutic delivery of carbon monoxide |
| 04/22/2009 | EP2049099A1 Compositions and methods for the treatment of mucositis |
| 04/22/2009 | EP2049098A2 Omega-3 fatty acids for use in treating resistant hypertension |
| 04/22/2009 | EP2049097A2 Composition and method for binding acetaldehyde in stomach |
| 04/22/2009 | EP2049096A2 Method of treating chronic myelogenous leukemia cells |
| 04/22/2009 | EP2049095A2 Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome |
| 04/22/2009 | EP2049094A2 Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia |
| 04/22/2009 | EP2049093A2 Pharmaceutical composition containing saredutant and a selective inhibitor of serotonin recapture or an inhibitor of serotonin/norepinephrine recapture in combination |
| 04/22/2009 | EP2049092A2 Compositions with enhanced elasticizing activity |
| 04/22/2009 | EP2049091A1 Casein complexes |
| 04/22/2009 | EP2049090A1 Use of 5-ht7 receptor agonists for the treatment of pain |
| 04/22/2009 | EP2049084A2 Nanoparticulate sorafenib formulations |
| 04/22/2009 | EP2049079A2 Compositions containing quaternary ammonium compounds |
| 04/22/2009 | EP2049007A1 Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects |
| 04/22/2009 | EP2048948A2 Liquid compositions of calcium acetate |
| 04/22/2009 | EP2003140A9 Galactose derivative, drug carrier and medicinal composition |
| 04/22/2009 | EP2002832A9 Composition containing lignan compound |
| 04/22/2009 | EP1931654B1 Modulators of metabolism and the treatment of disorders related thereto |
| 04/22/2009 | EP1893608A4 Thiazolyl mglur5 antagonists and methods for their use |
| 04/22/2009 | EP1851193B1 Hiv protease inhibitors |
| 04/22/2009 | EP1835907B1 Medicaments for the treatment or prevention of fibrotic diseases |
| 04/22/2009 | EP1830861B1 Antiviral and immunostimulating marine fish oil composition |
| 04/22/2009 | EP1830842B1 Medicaments for the treatment or prevention of fibrotic diseases |
| 04/22/2009 | EP1815853B1 Therapeutic agent ((-)-bpap) for drug dependence |
| 04/22/2009 | EP1802572B1 Indol derivatives as inhibitors of soluble adenylyl cyclase |
| 04/22/2009 | EP1795527B1 Carbamoyl-substituted spiro derivative |
| 04/22/2009 | EP1718651B1 7h-pyrrolopyrimidine derivatives |
| 04/22/2009 | EP1718632B1 Pyrimidine derivatives as orexin receptor antagonists |
| 04/22/2009 | EP1715883B1 18-membered nitrobenzyl-substituted and aminobenzyl-substituted cyclohexadepsipeptides for controlling endoparasites, and method for the production thereof |
| 04/22/2009 | EP1691808B1 Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative |
| 04/22/2009 | EP1689404B9 Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer |
| 04/22/2009 | EP1689391B1 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases |
| 04/22/2009 | EP1673354B1 Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists |
| 04/22/2009 | EP1670787A4 Cytokine inhibitors |
| 04/22/2009 | EP1641470B1 Vaginal compositions for treating pelvic tissue infections and traumas |
| 04/22/2009 | EP1628972B1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
| 04/22/2009 | EP1598079B1 Remedies for allergic contact dermatitis |
| 04/22/2009 | EP1592389B1 Piperazine-2-carboxamide derivatives |
| 04/22/2009 | EP1587805B1 Pharmaceutical process and compounds prepared thereby |
| 04/22/2009 | EP1585757A4 Peptide deformylase inhibitors |
| 04/22/2009 | EP1585518A4 Peptide deformylase inhibitors |
| 04/22/2009 | EP1572171B1 Reduction of breast density with 4-hydroxy tamoxifen |
| 04/22/2009 | EP1551865B1 Hybrid molecules of macrolides with steroidal/non-steroidal anti-inflammatory molecules |
| 04/22/2009 | EP1549305B1 Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of morbus alzheimer and morbus parkinson |
| 04/22/2009 | EP1539761B1 6,7-dihydro-5h-pyrazolo¬1,2-a pyrazol-1-ones which control inflammatory cytokines |
| 04/22/2009 | EP1531874B1 Embolic particles |
| 04/22/2009 | EP1528925B1 Quinazoline derivatives for use in the treatment of cancer |
| 04/22/2009 | EP1515704B1 Microcapsules for the delayed, controlled release of perindopril |
| 04/22/2009 | EP1507529B1 Combination comprising valsartan, amlodipine and hydrochlorothiazide |
| 04/22/2009 | EP1505974B1 Use of compounds that are effective as selective opiate receptor modulators |
| 04/22/2009 | EP1480630B1 Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa |
| 04/22/2009 | EP1425266B1 C2-substituted indane-1-ols and their derivatives, method for their production and their use as medicaments |
| 04/22/2009 | EP1387842B1 Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors |
| 04/22/2009 | EP1381366B1 Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| 04/22/2009 | EP1368004B1 Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine |
| 04/22/2009 | EP1334721B1 Nateglinide-containing hydrophilic drug preparations |
| 04/22/2009 | EP1317419B1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| 04/22/2009 | EP1285908B9 Substituted phenylpropionic acid derivatives |
| 04/22/2009 | EP1214088B1 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines |
| 04/22/2009 | EP1207809B1 Metering and packaging of controlled release medication |
| 04/22/2009 | EP1200455B1 Enzyme catalyzed therapeutic activation |
| 04/22/2009 | EP1200126B1 Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections |
| 04/22/2009 | EP1049459B1 Oral liquid compositions |